摘要
多重抗藥性結核病(multidrug-resistant tuberculosis)是指罹患至少對最重要的兩種抗結核藥物isoniazid及rifampicin抗藥的結核菌株之結核病。造成多重抗藥性結核病的原因很多，但最常見的原因多爲病人服藥順從性不佳或醫師不適當之治療療程。藉由短程直接觀察療法「都治計畫」(directly observed therapy, short-course; DOTS)的介入，能減少多重抗藥性結核病的產生。而對於多重抗藥性結核病而言，預防永遠是最好的策略。另外藉由「進階都治計劃」(DOTS-Plus)的介入，以期增加多重抗藥性結核病的治癒率。經由建構有效率的結核病防治體系，是預防及治療多重抗藥性結核病的重要策略。
並列摘要
Multidrug-resistant tuberculosis (MDR-TB) is defined by bacillary resistant to at least isoniazid and rifampicin in vitro. Although a great diversity of reasons accounting for MDR-TB, poor treatment adherence of patient or inappropriate prescription of physicians are still the major causes. Implementation of DOTS (directly observed therapy, short-course) could decrease incidence of MDR-TB. For MDR-TB, prevention is best strategy. Besides, implantation of DOTS-plus also could increase cure rate. To build efficacious framework system for managing tuberculosis is an important issue to prevent and treat MDR-TB.
被引用紀錄
延伸閱讀
- 程詩茹、杜美玉、王誠一、劉彥宏、林恒毅（2022）。廣泛抗藥性結核病。台灣醫學，26(4)，477-482。https://doi.org/10.6320/FJM.202207_26(4).0012
- Chien, J. T., & Lin, K. H. (2005). 多重抗藥性結核菌腰薦椎脊椎炎：一病例報告. Journal of Orthopaedic Surgery Taiwan, 22(3), 150-155. https://www.airitilibrary.com/Article/Detail?DocID=10116923-200509-22-3-150-155-a
- 賴志豪（2002）。淺談多重抗藥性結核菌。彰基藥訊，10(3)，10-15。https://doi.org/10.29600/BGYY.200209.0004
- 張惠淇、陳世欽（2010）。廣泛性抗藥性結核病。中南盟臨床專刊，3(2)，71-78。https://doi.org/10.29954/JMCSA.201010_3(2).0013
- Clain, J. M., & Escalante, P. (2016). Novel Treatments for Drug-Resistant Tuberculosis. Clinical Medicine Insights: Therapeutics, 2016(), 21-28. https://doi.org/10.4137/CMT.S18560